Labcorp (NYSE:LH) announced on November 17, 2026, a collaboration with Grupo Fleury to expand clinical trial operations in Brazil, with local kit assembly expected to begin in early 2027 and laboratory operations targeted for launch by the end of 2027.
Key Highlights
- New collaboration: Labcorp and Grupo Fleury, described in the filing as one of Brazil's leading healthcare and diagnostic groups, will work together to expand clinical trial operations in Brazil.
- Kit assembly timeline: Local clinical trial kit assembly operations are expected to begin in early 2027, according to the filing.
- Laboratory operations: Laboratory operations remain in development and are expected to launch by the end of 2027.
- Five-continent reach: The filing states the collaboration expands Labcorp's clinical trial support capabilities across five continents.
- Operational goals: Labcorp expects the Brazil presence to shorten kit delivery times, reduce reliance on international shipping, and improve operational efficiency for clinical trial sponsors.
- Global standards: Both operations will use Labcorp's global systems, processes, and quality standards to support multinational clinical trials, according to the filing.
Labcorp and Grupo Fleury Detail Brazil Clinical Trial Expansion Plans
According to the filing, Labcorp plans to launch local clinical trial kit assembly operations in Brazil first, followed by laboratory operations, with the collaboration structured to help sponsors conduct studies more efficiently while bringing services closer to research sites and patients. Labcorp's existing wholly owned central laboratory network spans North America, Europe, Asia, and Africa, and the company stated that this collaboration adds Brazil to that footprint, extending its reach across five continents.
The filing quotes Brian Caveney, M.D., president of biopharma laboratory services and chief medical and scientific officer at Labcorp, stating: "Clinical trials today often span multiple countries, and sponsors need partners that can combine global expertise with local insight." Edgar Rizzatti, president of Grupo Fleury's Medical, Technical, Hospitals, New Links and Innovation Business Unit, was also quoted, noting that the collaboration is intended to "help make clinical trials more efficient, broaden access to research opportunities and support the continued development of Brazil's clinical research ecosystem."
The filing describes Brazil as "a key destination for clinical research, supported by a diverse patient population and experienced investigators." Labcorp noted that the Grupo Fleury-supported operations will provide sponsors with local support while maintaining quality standards and data consistency used across its global network. The filing contains forward-looking statements regarding these plans and notes they are subject to change based on factors, many of which are beyond Labcorp's control, with actual results potentially differing materially from those described.
What Was Disclosed
Labcorp disclosed a collaboration with Grupo Fleury to establish clinical trial operations in Brazil, with kit assembly expected in early 2027 and laboratory operations by end of 2027, expanding the company's clinical trial support across five continents.




Please wait processing your request...